Mild Cognitive ImpairmentCognitive functionDrugPhase 2
What this study is
The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.
What's being tested
- Atorvastatin Oral Tablet
Intervention · DRUG
Atorvastatin pill 40 mg to be taken every night
Study details
- Official title
- Targeting Cerebrovascular Reactivity for Precision Medicine: Pilot Trial of Atorvastatin
- Sponsor
- Johns Hopkins University
- Conditions
- Mild Cognitive Impairment
- Enrolling
- 20 people
- Starts
- 2021-05-21
- Est. completion
- 2027-12-31
- Design
- Open-label, single group, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 60 Years – 95 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- MCI defined by Clinical Dementia Rating (CDR) of 0.5 or 1.0.
- Memory, processing speed, executive function, language - cognitive scores > 1.5 standard deviations below age-education norms.
- Not demented by history.
- Not taking statins currently or in the last 6 months.
- Cognitive/functional impairment not likely due to another neurological disease or delirium.
You can't join if
- Taking a statin currently or have taken a statin in the last 6 months.
- Contraindications to taking a statin.
- Transplant patient taking cyclosporine.
- Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal).
- Diagnosis of dementia by history.
- Current diagnosis of substance abuse.
- History of stroke or myocardial infarction in past 6 months.
- History of HIV.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openJohns Hopkins University, Bayview Medical Center
Baltimore, Maryland, United States
- Samantha Horn · Contact410-550-9020shorn8@jhmi.edu
- Ritu Agarwal · Contact410-550-9020ragarw19@jhmi.edu
- Paul Rosenberg, MD · Principal investigator
- Sevil Yasar, MD, PhD · Sub-investigator
Recruiting
Study team
Sponsor
Johns Hopkins University
Study ID IRB00256402
Principal investigator
Paul Rosenberg, MD
Johns Hopkins University
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.